Exploring the Promise of Targeting Ubiquitin-Proteasome System to Combat Alzheimer’s Disease
- 9 March 2020
- journal article
- review article
- Published by Springer Nature in Neurotoxicity Research
- Vol. 38 (1) , 8-17
Abstract
The ubiquitin (Ub)-proteasome system (UPS) is considered as a central protein degradation system in all eukaryotes. The UPS comprises of several factors such as Ub and Ub-like molecules, Ub hydrolases, E3 Ub ligases, and the proteasome itself. Numerous studies have demonstrated that the dysfunction of UPS plays an essential role in the pathogenesis and progression of Alzheimer’s disease (AD). Furthermore, current evidence has suggested that the UPS components can be connected with the initial stage of AD that is characterized by synaptic dysfunction, and to the late phases of AD, marked by neurodegeneration. In AD patients, the accumulations of insoluble protein in the brain can be caused by overload or dysfunction of the UPS, or by conformational alterations in the protein substrates that prevent their degradation and recognition by the UPS. Synaptic dysfunction is also caused by defective proteolysis that has found in the initial stage in AD as the UPS is widely recognized to play a pivotal role in the regular activities of synapses. Conversely, its precise cause and pathogenesis are unclear. Presently accepted medicines for AD give symptomatic relief, though they are unable to stop the progression of the disease. Besides, the components of the cellular quality control system demonstrate a significant emphasis on the advancement of targeted and effective treatments for AD. In this review, we focus on the role of UPS in the pathogenesis of AD and highlight how the UPS-linked treatments influence in the management of AD.Keywords
This publication has 87 references indexed in Scilit:
- KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer’s DiseaseCombinatorial Chemistry & High Throughput Screening, 2020
- N-Acetylcysteine in Combination with IGF-1 Enhances Neuroprotection against Proteasome Dysfunction-Induced Neurotoxicity in SH-SY5Y CellsParkinson's Disease, 2016
- The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosisScience Translational Medicine, 2015
- Targeting Hsp90 and its co-chaperones to treat Alzheimer’s diseaseExpert Opinion on Therapeutic Targets, 2014
- Turnover of C99 is Controlled by a Crosstalk between ERAD and Ubiquitin-Independent Lysosomal Degradation in Human Neuroglioma CellsPLOS ONE, 2013
- Therapeutic Effect of Exogenous Hsp70 in Mouse Models of Alzheimer's DiseaseJournal of Alzheimer’s Disease, 2013
- Crosstalk between the ubiquitin–proteasome system and autophagy in a human cellular model of Alzheimer's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Adapting Proteostasis for Disease InterventionScience, 2008
- The Role of the Ubiquitin–Proteasome Pathway in the Formation of Mallory BodiesExperimental and Molecular Pathology, 2002
- The ubiquitin-proteasome proteolytic pathwayCell, 1994